Physician profile
Robert K Smitherman
NPI 1760697668
$3,020.65
in general payments reported to CMS, 2019-2025
23 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2022: $277 · 2023: $823 · 2024: $787 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,614.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $624.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $574.38 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $350.84 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $241.65 | 2023-2025 | |
| Dexcom, INC. | $232.25 | 2023-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.13 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $142.51 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $117.96 | 2023-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $88.82 | 2019-2025 | |
| Exact Sciences Corporation | $73.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $63.51 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $58.44 | 2023-2024 | |
| Abbott Laboratories | $45.92 | 2024-2025 | Freestyle Libre |
| Abbvie INC. | $41.37 | 2022 | |
| Shield Therapeutics INC | $20.92 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $19.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.62 | 2023 | Xarelto |
| Seqirus USA INC | $14.98 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Idorsia Pharmaceuticals US INC | $14.79 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $14.58 | 2025 | Capvaxive, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $14.54 | 2024 | |
| Nestle Healthcare Nutrition INC. | $12.72 | 2022 | |
| Dynavax Technologies Corporation | $12.45 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smitherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.